结外自然杀伤/T细胞淋巴瘤的治疗研究进展
Research progress in the treatment of extranodal natural killer/T-cell lymphoma
张亚矗1
作者信息
- 1. 贵州医科大学临床医学院,贵州 贵阳 550000
- 折叠
摘要
结外自然杀伤/T细胞淋巴瘤(ENKTCL)是一种少见的与EB病毒感染相关的恶性肿瘤,具有较强的侵袭性.目前,对于晚期或复发/难治性ENKTCL,常规推荐使用含左旋门冬酰胺酶的非蒽环类药物联合其他药物进行化学治疗,但长期生存率仍较低.近年来,造血干细胞移植、免疫治疗和靶向治疗受到了广泛关注,为ENKTCL的治疗提供了新的选择.本文就造血干细胞移植、免疫治疗和靶向治疗在ENKTCL治疗中的应用进展进行综述.
Abstract
Extranodal natural killer/T-cell lymphoma(ENKTCL)is a rare malignant tumor associated with EB virus infection,with strong invasiveness.At present,for advanced or relapsed/refractory ENKTCL,it is recommended to use non-an-thracycline drugs containing L-asparaginase in combination with other drugs for chemotherapy,but the long-term survival rate is still low.In recent years,hematopoietic stem cell transplantation,immunotherapy and targeted therapy have received widespread attention,providing new options for the treatment of ENKTCL.This article reviews the therapeutic progress of hematopoietic stem cell transplantation,immunotherapy and targeted therapy in ENKTCL.
关键词
结外自然杀伤/T细胞淋巴瘤/复发/难治/造血干细胞移植/靶向治疗Key words
extranodal natural killer/T-cell lymphoma/recurrent/refractory/hematopoietic stem cell transplantation/targeted therapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据